• user warning: Got error 28 from storage engine query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 414937 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Got error 28 from storage engine query: SELECT DISTINCT(node.nid) AS nid, node_kaltura.kaltura_thumbnail_url AS node_kaltura_kaltura_thumbnail_url, node.title AS node_title, node_revisions.body AS node_revisions_body, node_revisions.format AS node_revisions_format, node_kaltura.kaltura_entryId AS node_kaltura_kaltura_entryId, node_kaltura.kaltura_plays AS node_kaltura_kaltura_plays, node_revisions.timestamp AS node_revisions_timestamp, node_kaltura.kaltura_duration AS node_kaltura_kaltura_duration, node_kaltura.kaltura_tags AS node_kaltura_kaltura_tags, node_kaltura.kaltura_admin_tags AS node_kaltura_kaltura_admin_tags, users.uid AS users_uid, users.name AS users_name, node.created AS node_created FROM node node LEFT JOIN node_kaltura node_kaltura ON node.nid = node_kaltura.nid LEFT JOIN node_revisions node_revisions ON node.vid = node_revisions.vid INNER JOIN users users ON node.uid = users.uid WHERE (node_kaltura.kaltura_media_type in ('1', '6')) AND (node_kaltura.kaltura_video_comment in ('0')) AND (node.status <> 0) AND ((node_kaltura.kaltura_tags) LIKE ('%%')) AND (node.created <= 1397927399-300) GROUP BY nid ORDER BY node_created DESC LIMIT 0, 6 in /var/www/www.fnno.com/htdocs/modules/views/includes/view.inc on line 771.

Shares of Halozyme Therapeutics Under Pressure, Down 1.3%

Published on Thu, 01/03/2013 - 11:37
By Peter Chu

Halozyme Therapeutics (NASDAQ:HALO) is one of today's notable stocks in decline, down 1.3% to $6.70. The S&P is trading fractionally lower to 1,460 and the Dow is trading 0.2% lower to 13,383.

There is potential upside of 33.3% for shares of Halozyme Therapeutics based on a current price of $6.70 and an average consensus analyst price target of $8.93. The stock should hit resistance at its 200-day moving average (MA) of $7.53, as well as support at its 50-day MA of $5.71.

Halozyme Therapeutics, Inc. develops and commercializes recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The Company's product portfolio is based on intellectual property covering the family of human enzymes known as hyaluronidases. Halozyme's products offer an alternative to slaughterhouse-derived extracts that carry contamination risks.

Over the past year, Halozyme Therapeutics has traded in a range of $3.86 to $13.50 and is now at $6.70, 74% above that low. The 200-day and 50-day moving averages have moved 1.04% lower and 0.59% higher over the past week, respectively.

By Peter Chu